The current role of mitoxantrone in the treatment of multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104(3):182-91
   PubMed Web of Science ®Google Scholar
• Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71(2):129-35
   PubMed Web of Science ®Google Scholar
• Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013;13:128
   PubMed Web of Science ®Google Scholar
• Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013;6:CD008933
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Therapy Consensus Group (MSTCG). Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255(10):1449-63
   Google Scholar
• Duddy M, Haghikia A, Cocco E, et al. Managing MS in a changing treatment landscape. J Neurol 2011;258(5):728-39
   PubMed Web of Science ®Google Scholar
• Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009;277:42-5
   PubMedGoogle Scholar
• Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs 2013;27(6):403-9
   PubMed Web of Science ®Google Scholar
• Sørensen PS. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. J Neurol Sci 2011;311:29-34
   PubMed Web of Science ®Google Scholar
• Hande KR. Topoisomerase II inhibitors. Update Cancer Ther 2008;3:13-26
   Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-9
   PubMed Web of Science ®Google Scholar
• Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62(2):112-18
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25
   PubMed Web of Science ®Google Scholar
• van de Wyngaert FA, Beguin C, D’Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101(4):210-16
   Google Scholar
• Miller JL. Mitoxantrone receives multiple-sclerosis indication. Am J Health Syst Pharm 2000;57(22):2038-40
   Google Scholar
• Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007;259(1-2):27-37
   PubMed Web of Science ®Google Scholar
• Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139(1):152-8
   Google Scholar
• Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178(10):6092-9
   PubMed Web of Science ®Google Scholar
• Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs’ mechanisms of action. Neurology 2010;74:41-6
   Google Scholar
• Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168(1-2):128-37
   Google Scholar
• Li JM, Yang Y, Zhu P, et al. Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol 2012;34(1):36-41
   PubMed Web of Science ®Google Scholar
• Axelsson M, Malmeström C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014;20(1):43-50
   PubMed Web of Science ®Google Scholar
• Ridge SC, Sloboda AE, McReynolds RA, et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 1985;35(1):35-42
   Google Scholar
• Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 1986;13(2):175-81
   Google Scholar
• Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987;45:122-8
   PubMedGoogle Scholar
• Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011;18(1):21-9
   PubMedGoogle Scholar
• Watson CM, Davison AN, Baker D, et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991;13:923-30
   PubMed Web of Science ®Google Scholar
• Mauch E, Kornhuber HH, Krapf H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242(2-3):96-102
   Google Scholar
• Krapf H, Mauch E, Fetzer U, et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995;37(2):113-19
   Google Scholar
• Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43(7):1401-6
   Google Scholar
• Bastianello S, Pozzilli C, D’Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21(3):266-70
   Google Scholar
• Krapf H, Morrissey SP, Zenker O, et al. MIMS Study Group. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005;65(5):690-5
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127
   PubMedGoogle Scholar
• Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79(1):52-6
   PubMed Web of Science ®Google Scholar
• Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007;13(8):975-80
   Google Scholar
• Esposito F, Radaelli M, Martinelli V, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2010;16(12):1490-9
   PubMed Web of Science ®Google Scholar
• Edan G, Comi G, Le Page E, French–Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011;82(12):1344-50
   PubMed Web of Science ®Google Scholar
• Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction. therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14(5):663-70
   Google Scholar
• Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005(4):CD002127
   Google Scholar
• Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol 2014;175(3):397-407
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74(18):1463-70
   PubMed Web of Science ®Google Scholar
• Goffette S, van Pesch V, Vanoverschelde JL, et al. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005;252(10):1217-22
   PubMed Web of Science ®Google Scholar
• Kingwell E, Koch M, Leung B, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74(22):1822-6
   PubMed Web of Science ®Google Scholar
• Killestein J, van der Meer ML, Regelink JC, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2010;74(11):934
   Google Scholar
• Pattoneri P, Sozzi F, Pelà G, et al. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis. Echocardiography 2009;26(4):397-402
   Google Scholar
• Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59(1):206-9
   Google Scholar
• Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004;135(1):49-55
   Google Scholar
• Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009;132(9):2517-30
   PubMed Web of Science ®Google Scholar
• Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008;14(9):1225-33
   PubMed Web of Science ®Google Scholar
• Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother 2013;13(3):251-60
   PubMed Web of Science ®Google Scholar
• Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21(11):2123-37
   PubMed Web of Science ®Google Scholar
• Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12(3):441-2
   PubMed Web of Science ®Google Scholar
• Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59(6):954-5
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8(5):441-5
   PubMed Web of Science ®Google Scholar
• Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012;5(2):75-9
   PubMed Web of Science ®Google Scholar
• Le Page E, Leray E, Edan G; French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17(7):867-75
   PubMed Web of Science ®Google Scholar
• Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77(21):1887-95
   Google Scholar
• Chan A, Lo-Coco F. Mitoxantrone-related acute leukemia in MS. An open or closed book? Neurology 2013;80:1529-33
   PubMed Web of Science ®Google Scholar
• Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112(8):3383-90
   Google Scholar
• Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011;96(4):621-5
   Google Scholar
• Ammatuna E, Montefusco E, Pacilli M, et al. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. Leuk Lymphoma 2009;50(7):1217-18
   PubMed Web of Science ®Google Scholar
• Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011;76(12):1059-65
   PubMed Web of Science ®Google Scholar
• Rivera VM, Jeffery DR, Weinstock-Guttman B, et al. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13(1):80
   PubMedGoogle Scholar
• Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab’s withdrawal. Arch Dermatol 2009;145(9):1037-9
   PubMedGoogle Scholar
• Sormani MP. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci 2009;287(1):46-9
   Google Scholar
• Stellmann JP, Neuhaus A, Herich L, et al. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data. PLoS One 2012;7(11):e50347
   Google Scholar